Vor Bio announced on July 18, 2025, that its Compensation Committee granted Qing Zuraw, M.D., the company’s Chief Development Officer, inducement awards in connection with her employment. These awards include 4,373,040 stock options and 937,080 restricted stock units (RSUs).
The stock options have a ten-year term and an exercise price of $2.38 per share, which was equal to the closing price of Vor Bio’s common stock on July 17, 2025. The options will vest over a four-year period, with 25% vesting after one year and the remainder monthly over the subsequent three years.
The RSUs will also vest over a four-year period, with 25% vesting on August 1, 2026, and the remaining shares vesting in equal quarterly installments over the following three years. These grants are designed to align Dr. Zuraw's long-term interests with the company's success in advancing its clinical pipeline.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.